Rapport Therapeutics stock soars after positive Phase 2a seizure drug results – Investing.com
- Rapport Therapeutics stock soars after positive Phase 2a seizure drug results Investing.com
- Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 Yahoo Finance
- Rapport Therapeutics To Report Epilepsy Trial Results On Monday – Will The Stock Surge Or Tumble? Nasdaq
- Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset MSN
- Rapport Therapeutics to Host Conference Call for Phase 2a Trial Topline Results of RAP-219 for Drug-Resistant Focal Onset Seizures Quiver Quantitative